One particular class of simulation-based models that have not yet benefited from the progression of Bayesian methods is the class of neurologically-plausible models of choice response time, in particular the Leaky, Competing Accumulator (LCA) model and the Feed-Forward Inhibition (FFI) model.
Yet, this ability declines with the progression of age in the older years.
This observation brings forth the notion that other, yet unknown modifying factors influence the progression of degeneration that leads to a symptomatic disorder.
One yet unaddressed issue is whether the progression of atherosclerosis is associated with an increase in DNA methylation drift in the vascular tissue.
Although we know that IF can have far-reaching, if not yet fully understood, effects on the progression of cancer, it can also be manipulated in the hope of promoting positive outcomes from treatment.
Yet the progression toward atonality also had a mystical aspect: these uncanny new chords could serve as esoteric icons, emblems of the sacred.
Pharmacological treatment is crucial for delaying the progression of diabetes, yet it remains inadequate in preventing the increased risk of CVD in patients with T2DM, especially women [ 6].
Interestingly, no specific molecular changes have yet been identified as associated with the progression of MGUS to MM: the genomic architecture of both diseases being remarkably similar.
Therefore, there is a strong interest in developing novel drugs that do not affect microtubule structures and yet are able to specifically inhibit the progression of mitosis.
Angiotensin II-subtype-1 (AT1) receptor blockers [ 5] or angiotensin-converting enzyme (ACE) inhibitors [ 6] slow the progression of CKD, yet they are contraindicated in bilateral renal artery stenosis or in unilateral renal artery stenosis and (functional) single kidney situation.
